Tectonic Therapeutic, Inc.

What they do

Tectonic discovers and develops therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs), using its proprietary GEODe (GPCRs Engineered for Optimal Discovery) platform. Its lead asset, TX45, is an Fc-relaxin fusion molecule activating the RXFP1 receptor, and its second candidate, TX2100, is a VHH-Fc antagonist antibody binding APJ (APLNR). The company is clinical-stage and reports no product revenue; it funds operations from its balance sheet.

Revenue drivers

• TX45 (Fc-relaxin fusion) — Lead program, no product revenue; being evaluated in the APEX Phase 2 trial in PH-HFpEF (Group 2 PH), with a separate Phase 2 trial in PH-ILD (Group 3 PH) started in March 2026.
• TX2100 (APJ antagonist antibody) — Second lead candidate for Hereditary Hemorrhagic Telangiectasia (HHT), in a Phase 1a healthy volunteer trial with topline expected by end of Q3 2026.
• GEODe discovery platform — Proprietary technology platform for discovering GPCR-targeted biologics; described as the basis for the pipeline rather than a current revenue source.

Recent performance

For the quarter ended June 30, 2026, Tectonic reported cash and cash equivalents of $227.1 million, including approximately $11.7 million in net proceeds from an at-the-market offering during the quarter. The company completed enrollment in the TX45 APEX Phase 2 trial in June 2026 with 191 patients across 14 countries, of which 137 had CpcPH and PVR > 3 WU. In July 2026 the IDMC reviewed unblinded safety and efficacy data covering approximately 80% of expected patient exposure and recommended continuation without modification. Dosing of the six single-dose cohorts in the TX2100 Phase 1a trial was completed in July 2026. No product revenue was reported.

Strategy

The company is prioritizing clinical execution on TX45 and TX2100 while funding operations from existing cash. For TX45, it plans topline APEX Phase 2 results early in Q1 2027 and is running a 16-week open-label Phase 2 trial in PH-ILD. For TX2100, subject to favorable safety, tolerability and pharmacokinetic results, it plans to advance into an open-label Phase 1b trial in hematologic-support dependent HHT patients and a placebo-controlled Phase 2 trial in moderate-to-severe HHT. The company also raised approximately $11.7 million net through an at-the-market offering in Q2 2026.

Risks

• Clinical trial failure risk — Both TX45 and TX2100 are unapproved candidates, and negative safety or efficacy results, including from the APEX Phase 2 or TX2100 Phase 1a trials, would materially impair the pipeline.
• No product revenue — The company has no approved products or product revenue, so operations depend on its cash balance and future financing.
• Cash runway dependency — Management states existing cash is expected to fund operations into Q1 2029, implying further dilution or financing may be needed beyond that point.
• Regulatory and development uncertainty — Discovery of biologics targeting GPCRs is described as historically difficult, and the company must still generate data sufficient to support later-stage trials and any eventual approval.

Outlook

Management expects topline results from the TX45 APEX Phase 2 trial in PH-HFpEF early in Q1 2027 and topline results from the TX2100 Phase 1a healthy volunteer trial by the end of Q3 2026. Subject to those results, TX2100 Phase 1b and Phase 2 trials in HHT are planned, with Phase 2 planned in early 2027. The company states its cash and cash equivalents of $227.1 million as of June 30, 2026 are expected to provide runway into Q1 2029.